Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Bolt Biotherapeutics, Inc.

NASDAQ: BOLT · Life Sciences · 8 alerts · CIK 1641281

Share price
$5.80Close, Nov 16
Market cap
$15.1M
Shares outstanding
2.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bolt Biotherapeutics, Inc. filings on SEC EDGAR ↗

6:03 AM ET 10-Q
Financial Results

Bolt Biotherapeutics Q3 2026 Results: Net Loss of $4.42M, Loss Narrows

Bolt Biotherapeutics reported a net loss of $19.5 million for the nine months ended September 30, 2026, a significant reduction from the $26.7 million loss in the prior year period. The company recently acquired Prana Therapies, Inc. to pivot its focus toward the INSPIRE platform for multispecific antibodies while completing Phase 1/2 trials for BDC-4182.

Key figure
Net loss $4.42M
4:12 PM ET 8-K
Financial Results

Bolt Biotherapeutics Financial Results

Bolt Biotherapeutics reported Q3 2026 financial results and provided a business update following its acquisition of Prana Therapies and a concurrent $120 million private placement. The company is shifting its primary focus to the INSPIRE-built pipeline, specifically the Phase 2 development of PRA-216 for inflammatory indications, with a cash runway extending into 2028.

“Completing the Prana acquisition marks an important transformation for Bolt. With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”

Willie Quinn, President and Chief Executive Officer

“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”

Sheila Gujrathi, M.D., Chief Strategy Officer
2:57 PM ET Form 4
Insider Buying

Bolt Biotherapeutics Insider Coastlands Capital LP Buys $319K of Stock

Coastlands Capital LP bought 50,000 shares of Bolt Biotherapeutics, Inc. at $6.38 a share, worth $319K in total on Nov 9, 2026. Shares held after the trade: 462,416 (+12.1%).

Value
$319K
Shares
50,000
Price
$6.38
Holding change
+12.1%
Trade date
Nov 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.